Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

Billal Tedbirt; Estelle Houivet; Maud Maho-Vaillant; Marie Laure Golinski; Sébastien Calbo; Catherine Prost-Squarcioni; Bruno Labeille; Catherine Picard-Dahan; Guillaume Chaby; Marie Aleth Richard; Emmanuelle Tancrède-Bohin; Sophie Duvert-Lehembre; Emmanuel Delaporte; Philippe Bernard; Frédéric Caux; Marina Alexandre; Philippe Musette; Saskia Ingen-Housz-Oro; Pierre Vabres; Gaëlle Quereux; Alain Dupuy; Sébastien Debarbieux; Martine Avenel-Audran; Michel D’Incan; Christophe Bédane; Nathalie Bénéton; Denis Jullien; Nicolas Dupin; Laurent Misery; Laurent Machet; Marie Beylot-Barry; Olivier Dereure; Bruno Sassolas; Nadège Cordel; Géraldine Jeudy; Jacques Benichou; Vivien Hébert; Pascal Joly

Journal ArticleOPEN ACCESS

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

JAMA Dermatology (2025) 161(4) 444-446

DOI: 10.1001/jamadermatol.2024.6654

5Citations

2Readers

Cite

CITATION STYLE

APA

Tedbirt, B., Houivet, E., Maho-Vaillant, M., Golinski, M. L., Calbo, S., Prost-Squarcioni, C., … Joly, P. (2025). Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris. JAMA Dermatology, 161(4), 444–446. https://doi.org/10.1001/jamadermatol.2024.6654

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

Cite

Register to see more suggestions